Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

INTRODUCTION: The phase III KEYNOTE-048 trial showed that the programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) ≥ 1 population and combined with platinum + 5-fluorouracil in the total population, improves survival over cetuximab + platinum + 5-fluoroura...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurcel, Victoria, Chirovsky, Diana, Borse, Rebekah, Altuna, Juan Ignacio, Carabajal, Fernando, Gandhi, Jyotika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107151/
https://www.ncbi.nlm.nih.gov/pubmed/33855690
http://dx.doi.org/10.1007/s12325-021-01656-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107151/
https://www.ncbi.nlm.nih.gov/pubmed/33855690
http://dx.doi.org/10.1007/s12325-021-01656-3

Ejemplares similares